Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.

Site Map

Site Map of http://www.researchandmarkets.com


- Site Map
- Pharmaceuticals and Healthcare
   - Pharmaceuticals 1 (Latest Titles)
   Pharmaceuticals 2
   Pharmaceuticals 3
   Pharmaceuticals 4

      - Oncology  << You are in This Category
    - Lung Cancer
    - Breast Cancer
    - Prostate Cancer
    - Leukemia
    - Lymphoma
    - Ovarian Cancer
    - Colon Cancer
    - Cervical Cancer
    - Brain Cancer
    - Bladder Cancer




#  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


#

25+ Business Development and Innovation Opportunities in Cancer Medicine - 2001 static version printer friendly pdf version


^ Top



A

An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology static version printer friendly pdf version
Analysis of Cancer Immunotherapy: The World Guide static version printer friendly pdf version
Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005 static version printer friendly pdf version
Analytical Tool - Cancer Vaccine static version printer friendly pdf version
Analytical Tool - Competitive Outlook on Apoptosis in Oncology static version printer friendly pdf version
Analytical Tool - Current & Future Therapies for Colorectal Cancer static version printer friendly pdf version
Analytical Tool - Hematological Cancers static version printer friendly pdf version
Analytical Tool: Cancer Vaccine static version printer friendly pdf version
Angiogenesis in Oncology: Drug Pipeline Update 2008 static version printer friendly pdf version
Angiogenesis Inhibitors 2001 - State-of-the-Science and Strategic Opportunities static version printer friendly pdf version
Anti-Angiogenics for Lung Cancer static version printer friendly pdf version
Antiangiogenic Drugs in Clinical Trial for Cancer static version printer friendly pdf version
Antibodies in Oncology: Drug Pipeline Update 2008 static version printer friendly pdf version
Antibody Drug Target Atlas in Oncology static version printer friendly pdf version
Antisense cancer therapies static version printer friendly pdf version
Antitumor Biologics - Strategies for Success in an Expanding Market static version printer friendly pdf version
Apoptosis in Oncology: Drug Pipeline Update 2008 static version printer friendly pdf version
Apoptosis: Promise Or Deception? static version printer friendly pdf version
Approval Outlook for Avastin® as a Breast Cancer Treatment: A Survey of Fifty Oncologists (Survey) static version printer friendly pdf version
Aromatase Inhibitors in Breast Cancer static version printer friendly pdf version
Aurora Kinase inhibitors - The dawn of a new approach to cancer static version printer friendly pdf version


^ Top



B

Basic Platform Report: Cancer Vaccines static version printer friendly pdf version
Benign Prostatic Hyperplasia: Expanding the drug treated population static version printer friendly pdf version
Biomarker Technology Platforms for Cancer Diagnoses and Therapies static version printer friendly pdf version
Biomedical Applications of Nanotechnology static version printer friendly pdf version
Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of Cancer static version printer friendly pdf version
Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer static version printer friendly pdf version
Bladder Cancer - High Recurrence Rates, Targeted Therapy to Stem the Flow? static version printer friendly pdf version
Blood Cancer Drug Discoveries: What the future holds static version printer friendly pdf version
Breast Cancer - Changing Treatment Paradigms For Local And Locally Advanced Breast Cancer static version printer friendly pdf version
Breast Cancer Opinion Leader Forum static version printer friendly pdf version
Breast Cancer Risk static version printer friendly pdf version
Brief Report: CD40 and CD40L (CD154) Agonists and Antagonists static version printer friendly pdf version
Brief Report: Death Receptors TRAIL-R1/2 static version printer friendly pdf version
Building Better Cancer Vaccines: The Progress and Promise of R&D static version printer friendly pdf version
Building on Early Successes of Immunomodulators in the Fight Against Cancer static version printer friendly pdf version


^ Top



C

Cancer - Emerging Cancer Therapeutics static version printer friendly pdf version
Cancer Antibodies: Competitive Positioning for Success static version printer friendly pdf version
Cancer Biology static version printer friendly pdf version
Cancer Biomarkers Conference 2008 static version printer friendly pdf version
Cancer Biomarkers: New Tools for Transforming Cancer Management static version printer friendly pdf version
Cancer Cell Therapy Markets static version printer friendly pdf version
Cancer Diagnostic Testing World Markets static version printer friendly pdf version
Cancer Diagnostics with DNA Microarrays static version printer friendly pdf version
Cancer Diagnostics: Early Detection of Breast, Prostate and Colorectal Cancer static version printer friendly pdf version
Cancer Drug Delivery: Managing Cancer Patients Beyond Oral Formulation static version printer friendly pdf version
Cancer Drug Discoveries: What the Future Holds static version printer friendly pdf version
Cancer Drug Discoveries: What the Future Holds: Breast Cancer Chapter static version printer friendly pdf version
Cancer Drug Discoveries: What the Future Holds: Colorectal Cancer Chapter static version printer friendly pdf version
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter static version printer friendly pdf version
Cancer Drug Discoveries: What the Future Holds: Renal Cancer Chapter static version printer friendly pdf version
Cancer Epidemiology and Prevention, Third Edition static version printer friendly pdf version
Cancer Gastrointestinal (Stomach) Cancer  static version printer friendly pdf version
Cancer genomics: The impact of genomic advances in oncology static version printer friendly pdf version
Cancer Head and Neck Cancer  static version printer friendly pdf version
Cancer in Children and Young People static version printer friendly pdf version
Cancer Kidney Cancer  static version printer friendly pdf version
Cancer Liver Cancer  static version printer friendly pdf version
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market static version printer friendly pdf version
Cancer Melanoma or Skin Cancer  static version printer friendly pdf version
Cancer Multiple Myeloma  static version printer friendly pdf version
Cancer Pancreatic Cancer  static version printer friendly pdf version
Cancer Personalized Medicine 2008 static version printer friendly pdf version
Cancer Stem Cells: Emerging Therapeutic, Diagnostic and Market Opportunities static version printer friendly pdf version
Cancer Survival Rates for American Blacks and Whites by Cancer Type static version printer friendly pdf version
Cancer Therapeutics 2006: Market Dynamics and R&D Trends static version printer friendly pdf version
Cancer Therapeutics Markets static version printer friendly pdf version
Cancer Therapeutics Markets static version printer friendly pdf version
Cancer Therapies - Is the United States Always the Most Expensive Market? static version printer friendly pdf version
Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan static version printer friendly pdf version
Cancer Therapy US Market Survey: Analysis and Forecast - Technology, Sales and Company Profiles static version printer friendly pdf version
Cancer Therapy Worldwide Market Survey: Analysis and Forecast - Technology, Sales and Company Profiles static version printer friendly pdf version
Cancer Vaccine Development and Projected Market Size static version printer friendly pdf version
Cancer Vaccine Developments to 2013 static version printer friendly pdf version
Cancer Vaccines and Tumor Immunity static version printer friendly pdf version
Cancer Vaccines Fantasy or Future? static version printer friendly pdf version
Cancer Vaccines Market, 2006-2010 static version printer friendly pdf version
Cancer Vaccines: A Class Poised For Expansion? static version printer friendly pdf version
Cancer Vaccines: Aim and Shoot static version printer friendly pdf version
Cancer Vaccines: Drug Pipeline Update 2008 static version printer friendly pdf version
Cancer Vaccines: Measuring Market Potential static version printer friendly pdf version
Cancer: From Mechanisms to Therapeutic Approaches static version printer friendly pdf version
Cancer: Immunotherapy Beyond Monoclonals static version printer friendly pdf version
Cell Junctions: Adhesion, Development, and Disease static version printer friendly pdf version
Cervical Cancer: Is Society Ready For a Preventative Answer? static version printer friendly pdf version
Challenges and Opportunities in Developing Chemopreventive Agents static version printer friendly pdf version
Challenges in Oncology Clinical Trial Design static version printer friendly pdf version
Changes in U.S. Oncology Drug Reimbursement: Medicare Sets the Pace static version printer friendly pdf version
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities static version printer friendly pdf version
Chinese Markets for Cancer Treatment Drugs static version printer friendly pdf version
Classes of Chemotherapy Drugs Used to Treat Breast Cancer static version printer friendly pdf version
Classes of Drugs Used to Treat Breast Cancer static version printer friendly pdf version
Colony Stimulating Factors State-of-the-Science and Strategic Opportunities static version printer friendly pdf version
Colorectal Cancer Drug Pipeline Update 2008 static version printer friendly pdf version
Commercial Insight Top 20 Cancer Therapeutics static version printer friendly pdf version
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006 static version printer friendly pdf version
Commercializing on Protein Kinase Inhibitors static version printer friendly pdf version
Commercializing on Tumor Antigens: Analytical Perspectives static version printer friendly pdf version
Companion Diagnostics in Personalized Medicine and Cancer Therapy static version printer friendly pdf version
Companion Diagnostics: Enabling Personalized Medicines in Cancer static version printer friendly pdf version
Comparison of Cancer Survival Rates, 1950 and 2000 static version printer friendly pdf version
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology static version printer friendly pdf version
Competitive Strategies in Cancer Medicine, 2000 static version printer friendly pdf version
Competitor Analysis: G-CSF & GM-CSF static version printer friendly pdf version
Competitor Analysis: PI3K-Akt-mTOR Pathway Inhibitors static version printer friendly pdf version
CRC Drug Pipeline Update 2005 static version printer friendly pdf version
Current Therapies for Ovarian Cancer static version printer friendly pdf version
Cytogen Corporation - SWOT Analysis static version printer friendly pdf version
Cytogen Corporation - SWOT Framework Analysis static version printer friendly pdf version
Cytotoxics for Lung Cancer Therapy static version printer friendly pdf version


^ Top



D

Decoding Big Pharma’s R&D Strategy in Oncology static version printer friendly pdf version
Developmental Cancer Vaccines static version printer friendly pdf version
Developments in Oncolytic Viruses - An Emerging Approach to Cancer Therapeutics static version printer friendly pdf version
Disease and Therapy Review: Melanoma static version printer friendly pdf version
Drug Approvals for Cancer Indications Alphabetical Listing, 1996-2002 static version printer friendly pdf version
Drug Delivery in Cancer - Technologies, Markets and Companies static version printer friendly pdf version
Drug Delivery Systems in Cancer Therapeutics static version printer friendly pdf version
Drugs in Development for Bladder Cancer static version printer friendly pdf version
Drugs in Development for Cancer, 2003 static version printer friendly pdf version
Drugs of Tommorow 2002: Breast Cancer static version printer friendly pdf version
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens static version printer friendly pdf version
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond static version printer friendly pdf version
Drugs of Tomorrow 2001: Cancer Overview static version printer friendly pdf version
Drugs of Tomorrow 2001: Lung Cancer static version printer friendly pdf version
Drugs of Tomorrow 2002: Colorectal Cancer static version printer friendly pdf version
Drugs of Tomorrow: Cancer Overview static version printer friendly pdf version
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies static version printer friendly pdf version
Drugs Used in Bladder Cancer Therapy static version printer friendly pdf version


^ Top



E

Elan Corporation - SWOT Framework Analysis static version printer friendly pdf version
Emerging Opportunities in Cancer Nanomedicine static version printer friendly pdf version
Emerging Technologies: Stem Cells, Genes and Monoclonal Antibodies static version printer friendly pdf version
Emerging Therapies for Ovarian Cancer static version printer friendly pdf version
Erythropoietin (EPO) Stimulating Agents: Impact of Proposed CMS Guidelines - A Survey of Fifty-three US-based Oncologists (Survey) static version printer friendly pdf version
Erythropoietin (EPO) Stimulating Agents: Trends in use in Oncology - A Panel Discussion among Eleven Community-based Oncologists static version printer friendly pdf version
European Bladder Cancer Therapeutics Markets static version printer friendly pdf version
European Head and Neck Cancer Therapeutics Markets static version printer friendly pdf version
European Support Cancer Therapy static version printer friendly pdf version
European Womens Cancer Pharmaceuticals Markets static version printer friendly pdf version


^ Top



F

Future Oncology static version printer friendly pdf version


^ Top



G

Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type static version printer friendly pdf version
Gastric Cancer: Looking to the East for Inspiration? static version printer friendly pdf version
Gastrointestinal (Stomach) Cancer Drug Pipeline Report static version printer friendly pdf version
Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market static version printer friendly pdf version
Global Cancer Focus Company Directory static version printer friendly pdf version
Global Pipeline Review & Analysis of Hematological Malignancies static version printer friendly pdf version
Growth in the European Market for Cancer Therapeutics, 1998-2007 static version printer friendly pdf version
Growth in the Japanese Market for Cancer Therapeutics, 1998-2007 static version printer friendly pdf version
Growth in the U.S. Market for Cancer Therapeutics, 1998-2006 static version printer friendly pdf version


^ Top



H

Head and Neck Cancer - Innovations to Change the Face of Treatment static version printer friendly pdf version
Head and Neck Cancer Drug Pipeline Report static version printer friendly pdf version
Helical/Arc-Based Radiation Oncology Equipment Assessment static version printer friendly pdf version
Hematological Cancers Drug Pipeline Update 2008 static version printer friendly pdf version


^ Top



I

Immunotherapy in Oncology: Drug Pipeline Update 2008 static version printer friendly pdf version
Immunotherapy in Oncology: Gaining Momentum static version printer friendly pdf version
Industry Analysis - How Companies Can Maintain the Market Success of Cancer MAbs static version printer friendly pdf version
Infections Causing Human Cancer static version printer friendly pdf version
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies static version printer friendly pdf version
Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution? static version printer friendly pdf version
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players static version printer friendly pdf version
Introduction to the Cellular and Molecular Biology of Cancer, Fourth Edition static version printer friendly pdf version


^ Top



J

Japanese Cancer Market: Who Will Emerge Ahead? static version printer friendly pdf version


^ Top



K

Key Trends in European Patient Monitoring Systems Market static version printer friendly pdf version
Key Trends in the Political and Reimbursement Environment for Cancer Drugs static version printer friendly pdf version
Kidney Cancer Drug Pipeline Report static version printer friendly pdf version


^ Top



L

Large Pharma: 2004 A Year Of Progress static version printer friendly pdf version
Latin American Oncology Therapeutics Markets static version printer friendly pdf version
Liver Cancer Drug Pipeline Report static version printer friendly pdf version
Liver Cancer Drug Pipeline Update 2008 static version printer friendly pdf version
Looking at the Cancer Therapy Market static version printer friendly pdf version


^ Top



M

Market Drivers: New Cancer Cases, 1998 and 2005 static version printer friendly pdf version
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail static version printer friendly pdf version
Market Potential of ACAPODENE® FOR ADT-Associated Osteoporosis: A Panel Discussion among Nine Physicians Specializing in the Treatment of Prostate Cancer static version printer friendly pdf version
MarketWatch: Cancer static version printer friendly pdf version
MarketWatch: Cancer static version printer friendly pdf version
MarketWatch: Cancer static version printer friendly pdf version
MarketWatch: Insight into Key Events in Cancer Therapeutics Area static version printer friendly pdf version
Marketwatch: Insight Into Key Events In The Cancer Industry static version printer friendly pdf version
Medicines in Development for Brain Cancer static version printer friendly pdf version
Medicines in Development for Cervical Cancer static version printer friendly pdf version
Melanoma Drug Pipeline Update 2008 static version printer friendly pdf version
Melanoma or Skin Cancer Drug Pipeline Report static version printer friendly pdf version
Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development static version printer friendly pdf version
Molecular-Targeted Pharmacotherapy in Myeloma: Clinical and Strategic Challenges on the Road to Commercialization static version printer friendly pdf version
Multiple Myeloma Drug Pipeline Report static version printer friendly pdf version


^ Top



N

New Approaches to the Treatment of Non-Hodgkins Lymphoma static version printer friendly pdf version
New Concepts in Cancer Therapeutics static version printer friendly pdf version
Niche Cancers 2001: Acute Myeloid Leukemia static version printer friendly pdf version
Niche Cancers 2001: Endometrial Carcinoma static version printer friendly pdf version
Niche Cancers 2001: Gastric Cancer static version printer friendly pdf version
Niche Cancers 2001: Glioblastoma static version printer friendly pdf version
Niche Cancers 2001: Head and Neck Cancer static version printer friendly pdf version
Niche Cancers 2001: Melanoma static version printer friendly pdf version
Niche Cancers 2001: Pancreatic Cancer static version printer friendly pdf version
Niche Cancers 2001: Renal Cell Carcinoma static version printer friendly pdf version
Niche Cancers 2001: Sarcoma static version printer friendly pdf version
Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers static version printer friendly pdf version


^ Top



O

Oncology Brand Commercialization: Resource Allocation static version printer friendly pdf version
Oncology Market Opportunities, Strategies, and Forecasts, 2006 To 2012 static version printer friendly pdf version
Oncology Pipelines: Is the Future Targeted Therapy? static version printer friendly pdf version
Opportunities and Challenges in the Japanese Market for Cancer Therapies static version printer friendly pdf version
Optimizing Targeted Treatment in Cancer: Negotiating the Challenges to Success static version printer friendly pdf version
Oral Cancer Therapies: Barriers and Pathways to Reimbursement static version printer friendly pdf version
Outlook for Cancer Vaccine Development static version printer friendly pdf version
Oxford Handbook of Oncology, Second Edition static version printer friendly pdf version


^ Top



P

Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged static version printer friendly pdf version
Pancreatic Cancer Drug Pipeline Report static version printer friendly pdf version
Pancreatic Cancer Drug Pipeline Update 2008 static version printer friendly pdf version
Partneringdesk Deals and Alliances in Oncology static version printer friendly pdf version
Partneringreview 2006: Biopharma Deal Making By Therapy Area - Oncology static version printer friendly pdf version
PharmaWatch: Cancer static version printer friendly pdf version
PharmaWatch: Cancer static version printer friendly pdf version
Phenotypic and Genotypic Diagnosis of Malignancies: An Immunohistochemical and Molecular Approach static version printer friendly pdf version
Pipeline Insight: Angiogenesis inibitors. Diversification and expansion of the innovatives class driving the evolution of cancer treatment static version printer friendly pdf version
Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation static version printer friendly pdf version
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward static version printer friendly pdf version
Pipeline Insight: Cancer Overview - Numerous Diverse Drugs Approaching Fruition static version printer friendly pdf version
Pipeline Insight: Immunostimulators: Diversification and expansion of the innovatives class driving the evolution of cancer treatment